Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Yf476

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
Phase 1 (3)
Phase 2 (1)

Trial Status

Completed4

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 4 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT01339169Phase 2Completed

YF476 and Type I Gastric Carcinoids

NCT01699113Phase 1CompletedPrimary

Effects of YF476 and Rabeprazole on Gastric Function

NCT01601405Phase 1CompletedPrimary

Effect of Repeated Doses of YF476 on Stomach Acidity

NCT01601418Phase 1CompletedPrimary

Effect of Single Doses of YF476 on Stomach Acidity

Showing all 4 trials

Research Network

Common Treatments

  • Yf4763
  • Netazepide1
  • Rabeprazole1

Active Sponsors

  • Trio Medicines Ltd.4
  • James Black Foundation2
  • Royal Liverpool University Hospital1

Top Investigators

Related Conditions

  • Type I Gastric Carcinoids1
  • Chronic Atrophic Gastritis1

Activity Timeline